Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.61 |
| ▸ | ATXN2 | Q99700 | 3/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25234685 | 0.85 | ENPP2 (0.58) | ENPP2ATXN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL25234683 | 0.85 | ENPP2 (0.58) | ENPP2ATXN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL25577610 | 0.84 | ENPP2 (0.57) | ENPP2ATXN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL13068970 | 0.84 | ENPP2 (0.53) | ENPP2ATXN2EPHX2HRH3GPBAR1 | |
| SCHEMBL12836705 | 0.82 | NPC1 (0.59) | ENPP2ATXN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL15540071 | 0.81 | ENPP2 (0.61) | ENPP2ATXN2 | |
| SCHEMBL12895459 | 0.81 | NPC1 (0.57) | ENPP2ATXN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL20669409 | 0.80 | NPC1 (0.63) | EPHX2MEN1ALDH1A1KMT2AFKBP1A | |
| SCHEMBL17761198 | 0.77 | ALDH1A1 (0.59) | ENPP2ATXN2EPHX2MEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17363099 | 0.75 | KDM4E (0.46) | ENPP2ATXN2KMT2AHRH3GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2020-07-02 | — | — | US | disclosed |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHE INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2017-02-02 | — | — | US | disclosed |
| EP-2861566-B1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN LA ROCHE (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-9493486-B2 | Diazaspirocycloalkane and azaspirocycloalkane | HOFFMANN-LA ROCHES INC. (US) | 2016-11-15 | — | — | US | disclosed |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200207769-A1 | DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | ENPP2 1/4885ATXN2 500/4885EPHX2 2939/4885 |
| US-20170029425-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | ENPP2, DAPK1, DAPK2 | ENPP2 1/4885ATXN2 280/4885EPHX2 3281/4885 |
| US-10633384-B2 | Diazaspirocycloalkane and azaspirocycloalkane | ENPP2, DAPK1, DAPK2 | ENPP2 1/4885ATXN2 500/4885EPHX2 2939/4885 |
| US-20150099734-A1 | NEW DIAZASPIROCYCLOALKANE AND AZASPIROCYCLOALKANE | DAPK2, DAPK1, IDH3A | ENPP2 548/4885ATXN2 1079/4885EPHX2 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.